Display options
Cite
Wallace ZS, Sparks JA, Robinson PC, et al. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks . Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-220960.
Wallace, Z. S., Sparks, J. A., Robinson, P. C., Machado, P. M., & Yazdany, J. (2021). Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-220960
Wallace, Zachary S, et al. "Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks ." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-220960
Wallace ZS, Sparks JA, Robinson PC, Machado PM, Yazdany J. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks . Ann Rheum Dis. 2021 Aug 23; doi: 10.1136/annrheumdis-2021-220960. Epub 2021 Aug 23. PMID: 34426400.
Copy Download .nbib Format: NLM
Share it on

Ann Rheum Dis. 2021 Aug 23; doi: 10.1136/annrheumdis-2021-220960. Epub 2021 Aug 23.

Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks .

Annals of the rheumatic diseases

Zachary S Wallace, Jeffrey A Sparks, Philip C Robinson, Pedro M Machado, Jinoos Yazdany

Affiliations

  1. Massachusetts General Hospital, Boston, Massachusetts, USA.
  2. Harvard Medical School, Boston, Massachusetts, USA.
  3. Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA [email protected].
  4. Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  5. Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
  6. Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia.
  7. MRC Centre for Neuromuscular Diseases, University College London, London, UK.
  8. Rheumatology, University College London Centre for Rheumatology, London, UK.
  9. Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA.

PMID: 34426400 DOI: 10.1136/annrheumdis-2021-220960

[No abstract available.]

Keywords: COVID-19; antirheumatic agents; biological therapy

Conflict of interest statement

Competing interests: JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253 and P30 AR07257

Publication Types